Dual Versus Single Antiplatelet Therapy in Patients Undergoing Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-analysis

Heart Lung and Circulation

Volumn 24, Issue 2, 2015, Pages 185-192

  Aryal, Madan Raj ^a   Karmacharya, Paras ^a   Pandit, Anil ^b   Hakim, Fayaz ^b   Pathak, Ranjan ^a   Mainali, Naba Raj ^a   Ukaigwe, Anene ^a   Mahmood, Maryam ^a   Badal, Madan ^a   Fortuin, F David ^b  

^a Reading Health System   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Dual antiplatelet therapy; Meta analysis; Single antiplatelet therapy; Systematic review; Transcatheter aortic valve replacement

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HUMAN; META ANALYSIS; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; RISK ASSESSMENT; SYSTEMATIC REVIEW; TRANSCATHETER AORTIC VALVE IMPLANTATION; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG COMBINATION; FEMALE; MALE; TIME;

ASPIRIN; DRUG THERAPY, COMBINATION; FEMALE; HEMORRHAGE; HUMANS; MALE; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; STROKE; TICLOPIDINE; TIME FACTORS; TRANSCATHETER AORTIC VALVE REPLACEMENT;

EID: 84921472321     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2014.07.058     Document Type: Article

References (27)

1. Durand E., Blanchard D., Chassaing S., Gilard M., Laskar M., Borz B., et al. Comparison of two antiplatelet therapy strategies in patients undergoing transcatheter aortic valve implantation. Am J Cardiol. 2014, 113(2):355-360. 10.1016/j.amjcard.2013.09.033.
2. Figini F., Latib A., Maisano F., Montorfano M., Chieffo A., Carlino M., et al. Managing patients with an indication for anticoagulant therapyafter transcatheter aortic valve implantation. Am J Cardiol. 2013, 111(2):237-242. 10.1016/j.amjcard.2012.09.023.
3. Lynch D.R., Dantzler D., Robbins M., Zhao D. Considerations in antithrombotic therapy among patients undergoing transcatheter aortic valve implantation. J Thromb Thrombolysis. 2013, 35(4):476-482. 10.1007/s11239-013-0886-z.
4. Poliacikova P., Cockburn J., de Belder A., Trivedi U., Hildick-Smith D. Antiplatelet and antithrombotic treatment after transcatheter aortic valve implantation - comparison of regimes. J Invasive Cardiol. 2013, 25(10):544-548.
5. Rodés-Cabau J., Dauerman H.L., Cohen M.G., Mehran R., Small E.M., Smyth S.S., et al. Antithrombotic treatment in transcatheter aortic valve implantation: insights for cerebrovascular and bleeding events. J Am Coll Cardiol. 2013, 62(25):2349-2359. 10.1016/j.jacc.2013.03.029.
6. Stepińska J., Czerwińska K., Witkowski A., Dabrowski M., Chmielak Z., Kuśmierski K., et al. Risk factors for bleeding complications in patients undergoing transcatheter aortic valve implantation (TAVI). Cardiol J. 2013, 20(2):125-133. 10.5603/CJ.2013.0024.
7. Leon M.B., Smith C.R., Mack M., Miller D.C., Moses J.W., Svensson L.G., et al. PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010, 363(17):1597-1607. 10.1056/NEJMoa1008232.
8. Davis E., Friedman S., Baker T. A Review of Antithrombotic Therapy for Transcatheter Aortic Valve Replacement. Postgrad Med. 2013, 125(1):59-72. 10.3810/pgm.2013.01.2625.
9. Ussia G.P., Scarabelli M., Mulè M., Barbanti M., Sarkar K., Cammalleri V., et al. Dual antiplatelet therapy versus aspirin alone in patients undergoing transcatheter aortic valve implantation. Am J Cardiol. 2011, 108(12):1772-1776. 10.1016/j.amjcard.2011.07.049.
10. Czerwińska-Jelonkiewicz K., Witkowski A., Dabrowski M., Banaszewski M., Ksiezycka-Majczyńska E., Chmielak Z., et al. Antithrombotic therapy - predictor of early and long-term bleeding complications after transcatheter aortic valve implantation. Arch Med Sci AMS. 2013, 9(6):1062-1070. 10.5114/aoms.2013.39794.
11. Hauville C., Ben-Dor I., Lindsay J., Pichard A.D., Waksman R. Clinical and silent stroke following aortic valve surgery and transcatheter aortic valve implantation. Cardiovasc Revascularization Med Mol Interv. 2012, 13(2):133-140. 10.1016/j.carrev.2011.11.001.
12. Higgins JPT GSe. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. In: The Cochrane Collaboration; 2011. Available at: Available from ; 2011. http://www.cochrane-handbook.org/.
13. Higgins J.P.T., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002, 21(11):1539-1558. 10.1002/sim.1186.
14. A Randomized Study Comparing double to single antiplatelet therapy for Transcatheter Aortic Valve Implantation. J Am Coll Cardiol. 2011, 58(20s1). SAT-TAVI (Single Antiplatelet Therapy for TAVI) study, B218-B218. 10.1016/j.jacc.2011.10.836.
15. Holmes D.R., Mack M.J., Kaul S., Agnihotri A., Alexander K.P., Bailey S.R., et al. American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance. 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement: developed in collabration with the American Heart Association, American Society of Echocardiography, European Association for Cardio-Thoracic Surgery, Heart Failure Society of America, Mended Hearts, Society of Cardiovascular Anesthesiologists, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Thorac Cardiovasc Surg. 2012, 144(3):e29-e84. 10.1016/j.jtcvs.2012.03.001.
16. Nishimura R.A., Otto C.M., Bonow R.O., Carabello B.A., Erwin J.P., Guyton R.A., et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014, 10.1016/j.jacc.2014.02.537.
17. Vahanian A., Alfieri O., Andreotti F., Antunes M.J., Baron-Esquivias G., Baumgartner H., et al. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). [Guidelines on the management of valvular heart disease (version 2012). The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)]. G Ital Cardiol 2006 2013, 14(3):167-214. 10.1714/1234.13659.
18. Webb J., Rodés-Cabau J., Fremes S., Pibarot P., Ruel M., Ibrahim R., et al. Transcatheter aortic valve implantation: a Canadian Cardiovascular Society position statement. Can J Cardiol. 2012, 28(5):520-528. 10.1016/j.cjca.2012.04.015.
19. Miller D.C., Blackstone E.H., Mack M.J., Svensson L.G., Kodali S.K., Kapadia S., et al. PARTNER Trial Investigators and Patients, PARTNER Stroke Substudy Writing Group and Executive Committee. Transcatheter (TAVR) versus surgical (AVR) aortic valve replacement: occurrence, hazard, risk factors, and consequences of neurologic events in the PARTNER trial. J Thorac Cardiovasc Surg. 2012, 143(4):832-843. e13. 10.1016/j.jtcvs.2012.01.055.
20. Tay E.L.W., Gurvitch R., Wijesinghe N., Nietlispach F., Nielispach F., Wood D., et al. A high-risk period for cerebrovascular events exists after transcatheter aortic valve implantation. JACC Cardiovasc Interv. 2011, 4(12):1290-1297. 10.1016/j.jcin.2011.08.012.
21. Mérie C., Køber L., Skov Olsen P., Andersson C., Gislason G., Skov Jensen J., et al. Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding. JAMA J Am Med Assoc. 2012, 308(20):2118-2125. 10.1016/j.jacc.2014.02.540.
22. Athappan G., Gajulapalli R.D., Sengodan P., Bhardwaj A., Ellis S.G., Svensson L., et al. Influence of TAVR strategy and Valve design on Stroke after Transcatheter Aortic Valve Replacement - A Meta-Analysis and Systematic Review of Literature. J Am Coll Cardiol. 2014, 10.1016/j.jacc.2014.02.540.
23. DeMaria A.N., Bax J.J., Feld G.K., Greenberg B.H., Hall J.L., Hlatky M.A., et al. Highlights of the Year in JACC 2012. J Am Coll Cardiol. 2013, 61(3):357-385. 10.1016/j.jacc.2012.12.002.
24. Vincentelli A., Susen S., Le Tourneau T., Six I., Fabre O., Juthier F., et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med. 2003, 349(4):343-349. 10.1056/NEJMoa022831.
25. Warkentin T.E., Moore J.C., Morgan D.G. Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand's disease the link?. Lancet. 1992, 340(8810):35-37.
26. SPS3 Investigators, Benavente O.R., Hart R.G., McClure L.A., Szychowski J.M., Coffey C.S., et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012, 367(9):817-825. 10.1056/NEJMoa1204133.
27. Aspirin Versus Aspirin {thorn} Clopidogrel Following Transcatheter Aortic Valve Implantation: the ARTE trial. 2012. Available at: Accessed March 14, 2014. http://clinicaltrials.gov/ct2/show/nct01559298%3Fterm%25BCnct01559298%26rank%25BC1.